OneAscent Financial Services LLC Increases Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

OneAscent Financial Services LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 45.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,426 shares of the biopharmaceutical company’s stock after buying an additional 1,376 shares during the quarter. OneAscent Financial Services LLC’s holdings in Gilead Sciences were worth $409,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. HHM Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 154 shares in the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the 4th quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter worth about $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences in the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC lifted its position in Gilead Sciences by 325.0% during the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Up 0.4 %

GILD opened at $112.39 on Friday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm’s 50 day simple moving average is $107.02 and its two-hundred day simple moving average is $95.63. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $139.94 billion, a PE ratio of 303.76, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.81%. Gilead Sciences’s payout ratio is 854.05%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. This represents a 9.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GILD. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. The Goldman Sachs Group raised their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, February 12th. Wells Fargo & Company boosted their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and increased their price objective for the company from $80.00 to $120.00 in a research report on Tuesday, February 18th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.